The latest news:

• Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.        I have written a lot about this drug (Onc-201) lately - I am excited about it and we (the Musella Foundation) have a special interest in it because we gave grants to help them get this far!  This study shows that it may also be good to treat many other types of tumors that overexpress the target!  Right now for brain tumors it is in clinical trials for DIPG and high grade gliomas that have the H3 K27M mutation - which usually occurs in younger people with tumors in the midline of the brain.
  



• Penn Medicine Launching Telemedicine Platform for Brain Tumor Consults         Dr Brem is another one of my favorites.  They offer proton bram radiation and immunotherapy trials including CAR-T cell which is one of the most promising new treatments.
  



• FDA TO FACILITATE ACCESS TO UNAPPROVED DRUGS        

  This sounds like a great program. We have been helping patients get access to experimental treatments for a while and it takes a lot of time on our part, the doctor’s part and the drug companies' part.  I hope that this will smooth things over.

  If anyone tries it, please let me know how it works out!

   
  

BrainTumor Co-Payment Assistance Program Status:

• CLOSED to new applicants